UnitedHealth Group lifted its 2026 adjusted earnings outlook to at least $20.50 a share from a prior range of $19.50 to $20, the clearest signal yet that the insurer's margin-repair plan is taking hold. The revision came alongside a third quarter that topped consensus on every headline metric, sending shares up roughly 3% before the open.
The numbers that mattered
Adjusted earnings came in at $4.69 a share, well above the $4.14 analysts had penciled in. Revenue of $112.69 billion also cleared the $111.40 billion estimate, though it slipped from $113.16 billion a year earlier. On a GAAP basis the company earned $4.56 a share, up from $2.59 in the same quarter last year, with net income nearly doubling to $4.11 billion. The beat was driven almost entirely by the medical cost ratio, which landed at 88.4% versus the 89.9% StreetAccount forecast, a 150-basis-point cushion that translates directly into underwriting margin.
Medical costs are still running hot
CFO Wayne DeVeydt was blunt: underlying medical-cost trends remain elevated compared with pre-pandemic norms, a dynamic that has dogged Medicare Advantage carriers for more than two years. He flagged the independent dispute resolution process under the No Surprises Act as a structural headwind, adding at least one full percentage point to total medical costs. Inpatient utilization and specialty pharmacy, particularly oncology and rare-disease drugs, continue to push claims higher, costs that ultimately feed into premium renewal cycles.
The utilization shift is real
The company's value-based care investments are showing up in utilization patterns. Acute hospital admissions across the membership base fell 15% year to date through September, while home-health admissions rose 10%. That migration toward lower-acuity settings is the mechanism through which UnitedHealth intends to bend the cost curve, and the early data suggest it is working, even if the aggregate medical-cost ratio still sits well above the low-80s range the industry once considered normal.
Guidance implies confidence, not complacency
Raising the floor on full-year adjusted EPS by a dollar at the midpoint is a meaningful commitment. It implies the insurer sees the current medical-cost ratio as sustainable, or at least manageable, through the back half of the year. The market's premarket reaction suggests investors are willing to credit the turnaround narrative, three straight quarters of execution, membership pruning, and AI-driven efficiency gains, but the real test will be whether the 88% medical-cost ratio holds when flu season and the next round of Medicare Advantage rate notices arrive.